Published in Diabetologia on December 01, 1977
Nesidioblastosis of the pancreas: definition of the syndrome and the management of the severe neonatal hyperinsulinaemic hypoglycaemia. Arch Dis Child (1981) 2.36
Surgical treatment of hyperinsulinaemic hypoglycaemia in infancy and childhood. Arch Dis Child (1992) 1.49
Insulinoma producing progressive neurological deterioration over 30 years. Br Med J (Clin Res Ed) (1986) 1.03
Processing and secretion of nerve growth factor: expression in mammalian cells with a vaccinia virus vector. Mol Cell Biol (1988) 1.02
Differentiation of insulin secretion patterns in insulinoma. World J Surg (2008) 0.94
Hypoglycemias. West J Med (1991) 0.82
Human Insulinomas: Clinical, Cellular, and Molecular Aspects. Endocr Pathol (1999) 0.79
Multiple endocrine neoplasia syndromes. West J Med (1980) 0.75
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (2000) 10.66
Metformin. N Engl J Med (1996) 7.66
A sensitive, precise radioimmunoassay of serum insulin relying on charcoal separation of bound and free hormone moieties. Acta Endocrinol (Copenh) (1972) 7.64
UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia (2001) 4.78
Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A (1987) 4.19
Radioimmunological determination of human C-peptide in serum. Diabetologia (1975) 4.02
Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res (1988) 3.10
Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med (1983) 3.07
Impact of pharmaceutical company representatives on internal medicine residency programs. A survey of residency program directors. Arch Intern Med (1992) 2.95
United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol (1998) 2.93
Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med (1999) 2.75
Linkage of type 2 diabetes to the glucokinase gene. Lancet (1992) 2.64
Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia (1972) 2.63
Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med (1988) 2.43
Decreases in albumin/creatinine and N-acetylglucosaminidase/creatinine ratios in urine samples stored at -20 degrees C. Clin Chem (1992) 2.41
Nesidioblastosis of the pancreas: definition of the syndrome and the management of the severe neonatal hyperinsulinaemic hypoglycaemia. Arch Dis Child (1981) 2.36
Small doses of intramuscular insulin in the treatment of diabetic "coma". Lancet (1973) 2.36
Characterization of seven C-peptide antisera. Diabetes (1978) 2.29
Cyclic oscillations of basal plasma glucose and insulin concentrations in human beings. N Engl J Med (1979) 2.25
Home blood sampling for plasma glucose assay in control of diabetes. Br Med J (1978) 2.22
UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med (1998) 2.20
Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). UK Prospective Diabetes Study Group. Diabet Med (2000) 2.20
Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet (1987) 2.15
Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism (1979) 2.07
Parent-offspring trios: a resource to facilitate the identification of type 2 diabetes genes. Diabetes (1999) 1.97
Radioimmunological determination of pancreatic and gut glucagon in plasma. Diabetologia (1971) 1.91
Hypoglycaemia in African children with severe malaria. Lancet (1987) 1.88
Can residents be trained to counsel patients about quitting smoking? Results from a randomized trial. J Gen Intern Med (1991) 1.81
A practical guide to basal and prandial insulin therapy. Diabet Med (1985) 1.76
Diabetes: The quest for basal normoglycaemia. Lancet (1977) 1.75
Approach to maintaining comparability of biochemical data during long-term clinical trials. Clin Chem (1997) 1.70
Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familial type 2 diabetes. Lancet (1986) 1.61
Pulsatile insulin has greater hypoglycemic effect than continuous delivery. Diabetes (1983) 1.61
Effect of sustained maternal hyperglycaemia on the fetus in normal and diabetic pregnancies. Br Med J (1972) 1.59
Clinical aspects of insulin--antigenicity. Diabetes (1972) 1.55
Genetic susceptibility to the development of retinopathy in insulin-dependent diabetics. Diabetes (1982) 1.53
Control of basal insulin secretion, with special reference to the diagnosis of insulinomas. Br Med J (1971) 1.48
Persistent obesity in rats following a period of consumption of a mixed, high energy diet. J Physiol (1980) 1.48
Basal normoglycemia attained with chlorpropamide in mild diabetes. Metabolism (1978) 1.47
Optimizing blood glucose control in type 2 diabetes: an approach based on fasting blood glucose measurements. Diabet Med (1988) 1.45
Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man. Diabetologia (1985) 1.44
Can life-styles of subjects with impaired glucose tolerance be changed? A feasibility study. Diabet Med (1992) 1.43
'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance. Q J Med (1993) 1.43
Measurement of the insulin delivery rate in man. J Clin Endocrinol Metab (1971) 1.42
Haemolysis affects insulin but not C-peptide immunoassay. Diabetologia (1987) 1.41
Brief, irregular oscillations of basal plasma insulin and glucose concentrations in diabetic man. Diabetes (1981) 1.40
Type II diabetes of early onset: a distinct clinical and genetic syndrome? Br Med J (Clin Res Ed) (1987) 1.39
Microaneurysms in the development of diabetic retinopathy (UKPDS 42). UK Prospective Diabetes Study Group. Diabetologia (1999) 1.38
Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia (1999) 1.36
Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. Diabetes (1999) 1.36
Quinine and severe falciparum malaria in late pregnancy. Lancet (1985) 1.34
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44) Diabetes Care (1999) 1.32
Prospective comparison of modified fat-high-carbohydrate with standard low-carbohydrate dietary advice in the treatment of diabetes: one year follow-up study. Br J Nutr (1978) 1.32
Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin secretion defect. J Clin Invest (1997) 1.30
C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control. Acta Paediatr Scand (1977) 1.29
Control of pulsatile insulin secretion in man. Diabetologia (1983) 1.29
Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J (1976) 1.28
Suppression of insulin release by fish-insulin-induced hypoglycaemia: with reference to the diagnosis of insulinomas. Lancet (1973) 1.27
Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia (1997) 1.27
Association of low birth weight with beta cell function in the adult first degree relatives of non-insulin dependent diabetic subjects. BMJ (1993) 1.27
Mutations in the hepatocyte nuclear factor-1alpha gene in MODY and early-onset NIDDM: evidence for a mutational hotspot in exon 4. Diabetes (1997) 1.26
Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. Br Med J (Clin Res Ed) (1986) 1.22
Automatic lancet for capillary blood sampling. Lancet (1978) 1.21
Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabet Med (2001) 1.19
A simple and rational twice daily insulin regime. Distinction between basal and meal insulin requirements. Q J Med (1979) 1.18
Glucagon radioimmunoassay using antiserum 30K: interference by plasma. Horm Metab Res (1973) 1.17
Human C-peptide in normal and diabetic subjects. Diabetologia (1975) 1.16
General practice care of non-insulin-dependent diabetes with fasting blood glucose measurements. Am J Med (1982) 1.16
C-peptide in children with juvenile diabetes. A preliminary report. Diabetologia (1976) 1.15
Human ultralente insulin. Br Med J (Clin Res Ed) (1984) 1.14
Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement. Diabet Med (1987) 1.14
Control of maturity-onset diabetes by monitoring fasting blood glucose and body weight. Diabetes Care (1981) 1.14
High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests. Diabet Med (1995) 1.12
Pulsatile, synchronous basal insulin and glucagon secretion in man. Diabetes (1982) 1.10
Diabetes mellitus, Addison's disease and pernicious anaemia. Postgrad Med J (1968) 1.10
Clinical characteristics of subjects with a missense mutation in glucokinase. Diabet Med (1995) 1.09
Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment. Diabet Med (1988) 1.08
Twenty-four-hour metabolic profiles in diabetic children receiving insulin injections once or twice daily. Br Med J (1980) 1.07
The diabetes prevention program. Diabetes Care (1999) 1.07
Missense glucokinase mutation in maturity-onset diabetes of the young and mutation screening in late-onset diabetes. Nat Genet (1992) 1.06
Twenty-four hour profiles of plasma C-peptide in type 1 (insulin-dependent) diabetic children. Diabetologia (1982) 1.05
beta-cell function in children with diabetes. Diabetes (1978) 1.05
Detection of mutations in insulin-receptor gene in NIDDM patients by analysis of single-stranded conformation polymorphisms. Diabetes (1991) 1.04
Sequence variants in the pancreatic islet beta-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM. Diabetes (1997) 1.04
Type 2 (non-insulin-dependent) diabetes mellitus. New genetics for old nightmares. Diabetologia (1988) 1.03
Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism (1989) 1.03
U.K. Prospective Diabetes Study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM. Diabetes Care (1997) 1.03
Localisation of islet amyloid peptide in lipofuscin bodies and secretory granules of human B-cells and in islets of type-2 diabetic subjects. Cell Tissue Res (1989) 1.02
Understanding "insulin resistance": both glucose resistance and insulin resistance are required to model human diabetes. Metabolism (1991) 1.00
Endocrine and metabolic response in the human newborn to first feed of breast milk. Arch Dis Child (1977) 1.00
Hypogonadism and muscular dystrophy. Proc R Soc Med (1966) 0.99
Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in while Caucasian subjects or evidence of abnormal function when expressed in vitro. Diabetologia (1996) 0.99
Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47). Am Heart J (1999) 0.99
Pancreatic-glucagon-like immunoreactivity after intravenous insulin in normals and chronic-pancreatitis patients. Acta Endocrinol (Copenh) (1971) 0.98
Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia (1990) 0.98
The basal plasma glucose: a simple relevant index of maturity-onset diabetes. Clin Endocrinol (Oxf) (1981) 0.98
Retinal pigment epithelial change and partial lipodystrophy. Postgrad Med J (1988) 0.98